Myriad Genetics (MYGN) Shares Outstanding (Weighted Average) (2016 - 2025)
Historic Shares Outstanding (Weighted Average) for Myriad Genetics (MYGN) over the last 13 years, with Q3 2025 value amounting to $93.1 million.
- Myriad Genetics' Shares Outstanding (Weighted Average) rose 242.02% to $93.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.1 million, marking a year-over-year increase of 242.02%. This contributed to the annual value of $90.6 million for FY2024, which is 942.03% up from last year.
- Myriad Genetics' Shares Outstanding (Weighted Average) amounted to $93.1 million in Q3 2025, which was up 242.02% from $92.5 million recorded in Q2 2025.
- In the past 5 years, Myriad Genetics' Shares Outstanding (Weighted Average) ranged from a high of $93.1 million in Q3 2025 and a low of $76.0 million during Q1 2021
- Over the past 5 years, Myriad Genetics' median Shares Outstanding (Weighted Average) value was $81.7 million (recorded in 2023), while the average stood at $84.1 million.
- Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first surged by 148.7% in 2023, then surged by 1098.9% in 2024.
- Myriad Genetics' Shares Outstanding (Weighted Average) (Quarter) stood at $78.0 million in 2021, then grew by 3.33% to $80.6 million in 2022, then grew by 2.73% to $82.8 million in 2023, then rose by 9.42% to $90.6 million in 2024, then grew by 2.76% to $93.1 million in 2025.
- Its Shares Outstanding (Weighted Average) was $93.1 million in Q3 2025, compared to $92.5 million in Q2 2025 and $91.4 million in Q1 2025.